Takeda to Stop Manufacturing Natpara at the End of 2024
Takeda said it will stop manufacturing Natpara (parathyroid hormone) for injection as a treatment for patients with hypoparathyroidism at the end of 2024.
The decision was made because of unresolved supply and manufacturing challenges that are specific to the product, the company said.
Takeda said it intends to maintain treatment continuity for patients who are currently receiving Natpara until the end of 2024, subject to available supply.
This includes about 400 patients enrolled in the U.S. special use program and all patients receiving the drug in Europe and other regions around the world, where it is sold as Natpar.